Apellis Pharmaceuticals Inc. (APLS), Thursday, announced that it expects the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, to adopt a negative opinion on the authorization application of intravitreal Pegcetacoplan.
from RTT - Before the Bell https://ift.tt/6zJEOxc
via IFTTT
No comments:
Post a Comment